Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095092 | 0.86 | S1PR5 (0.37) | S1PR1S1PR5 | |
| SCHEMBL2799997 | 0.78 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL28505033 | 0.75 | SIRT2 (0.50) | — | |
| SCHEMBL23601750 | 0.73 | APP (0.39) | — | |
| SCHEMBL4083198 | 0.72 | GRM2 (0.41) | — | |
| SCHEMBL2797957 | 0.72 | SIRT2 (0.50) | — | |
| SCHEMBL31139283 | 0.72 | SIRT2 (0.50) | — | |
| SCHEMBL17153130 | 0.71 | ALDH1A1 (0.36) | — | |
| SCHEMBL20857626 | 0.71 | IDO1 (0.33) | — | |
| SCHEMBL18338150 | 0.71 | THRA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | S1PR1 1120/4885S1PR5 2429/4885PDGFRA 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.